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Abstract
Antibody gene transfer, which involves the delivery of genes that encode potent, broadly 
neutralizing anti-HIV antibodies, is a promising new strategy to prevent HIV infection. A satellite 
symposium at the AIDS Vaccine 2012 conference brought together many of the groups working in 
this field.
Despite nearly thirty years of intense study, efforts to develop a safe and effective HIV 
vaccine by conventional means have either failed or provided only modest, short-lived 
protection. While the tantalizing results of the HIV vaccine trial RV144 in Thailand 
continue to guide efforts to improve the efficacy and duration of a vaccine that harnesses the 
natural immune system, it remains uncertain when or if such efforts will succeed.
Recent studies describing the discovery of more potent, broadly neutralizing antibodies 
targeting HIV from chronically infected patients have revealed the potential for the humoral 
response to produce protective antibodies during the course of natural infection1,2. However, 
it is unclear whether immunogens can be designed that will elicit these rare antibodies 
efficiently.
Antibody gene transfer is a novel protective strategy that bypasses the natural immune 
response, which has been the central focus of previous attempts to develop an HIV vaccine, 
by directing the production of antibodies from non-hematopoietic tissues, such as muscle 
(Figure 1). Because this approach skips many of the steps in the usual path of vaccine 
development, it has been described as a leapfrog strategy. Recent advances in the use of 
gene transfer for the correction of genetic deficiencies3,4 – particularly the successful 
expression of factor IX in a small group of Hemophilia B patients – have bolstered the 
intriguing possibility of utilizing adeno-associated virus (AAV) vectors as a vehicle for 
antibody gene delivery in humans. Two recent studies have demonstrated the feasibility of 
this approach against both SIV in macaques5 as well as HIV in humanized mice6.
The Foundation for Vaccine Research (FVR) organized a special satellite symposium at the 
AIDS Vaccine 2012 conference in September in Boston to discuss the latest developments 
in this promising area of translational research.
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AAV-Mediated Delivery of Broadly Neutralizing Antibodies
To provide a framework for the session, Phil Johnson (Children's Hospital of Philadelphia) 
delivered a comprehensive introduction to the biology and history of adeno-associated virus 
(AAV) vectors. A member of the parvoviridae family, AAV is a ubiquitous commensal 
virus in humans that has never been associated with any disease. It consists of a protein 
capsid shell that surrounds a single-strand of genomic DNA that encodes just two viral 
genes (Rep and Cap), flanked on either side by inverted-terminal repeat sequences (ITRs). 
These ITRs form unique hairpin structures that, in conjunction with Rep and Cap, mediate 
both DNA replication and packaging during virus production. Natural AAV propagation is 
entirely dependent upon co-infection with adenovirus to deliver necessary helper factors in 
trans. To produce AAV vectors for immunoprophylaxis, a desired antibody transgene is 
inserted between two ITR sequences and can be packaged into viral particles by co-
transfection with plasmid expressing the desired Rep and Cap genes as well as a separate 
plasmid to provide adenoviral helper functions. The serotype of the AAV vector produced is 
the result of the capsid gene, which impacts both the cellular tropism of the vector as well as 
biological properties such as intracellular trafficking. AAV serotypes 1 and 8 have both been 
found to efficiently infect muscle tissues to form episomal head-to-tail concatamers of their 
genome in the nucleus, which result in very long-lived, high-level gene expression in 
animals models and have demonstrated excellent safety and tolerability in previous human 
trials. Presenting follow-up data from his 2009 study of anti-SIV immunoadhesins-based 
protection of macaques given AAV1 in macaques5, Johnson showed that animals expressing 
the 4L6 immunoadhesin have sustained circulating concentrations of approximately 
20µg/mL of protein for the past five years with no adverse health effects following the four 
intramuscular injections given at the initiation of the study. These results are consistent with 
previous AAV studies in macaques that demonstrated stable erythropoietin expression for 
over 6 years7 and raise the hope that similar longevity of immunoprophylaxis might be 
achieved in human patients.
Animal models of Immunoprophylaxis
Following the first descriptions of broadly neutralizing antibodies 2F5, 4E10, b12 and 2G12, 
a number of passive transfer studies were undertaken to determine their efficacy in 
preventing infection with SIV-HIV-1 hybrid virus (SHIV) in macaques. Since this time, 
newer neutralizing antibodies have been described with considerably higher potency in 
vitro, raising the possibility that lower in vivo concentrations might be sufficient to provide 
protection. Dennis Burton (Scripps) confirmed this possibility during the session by 
presenting early results of experiments in which PGT121 exhibited remarkable protection in 
macaques. Animals given 5mg/kg, 1mg/kg or 0.2mg/kg doses of PGT121 exhibited 
approximately 100µg/mL, 15µg/mL or 2µg/mL of antibody in circulation one day after 
administration and just prior to intravaginal challenge with 300 TCID50 of SHIV162P3. At 
the vaginal surface, PGT121 was detected at 0.9µg/mL and 0.2µg/mL respectively in 
animals receiving 5mg/kg and 1mg/kg doses and was undetectable in animals that received 
0.2mg/kg. Following challenge, animals in the 5mg/kg and 1mg/kg groups remained 
uninfected, while 3/5 of animals receiving 0.2mg/kg PGT121 were protected from 
challenge, despite a lack of detectable antibody at the vaginal surface. These results 
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represent an improvement over original studies of b12 in which 25mg/kg protected 8/9 
animals from a similar challenge8.
Human-to-human mucosal transmission of HIV requires the virus to mobilize across 
significant host barriers, resulting in only one or a handful of viruses initiating most 
infections9,10. Substantial effort has been directed towards understanding the unique 
characteristics of such transmitted founder strains of HIV that have succeeded in this 
process11. While enhanced resistance to neutralizing antibodies has not been observed for 
these strains10,11, it was unclear whether infection by such strains in vivo would exhibit 
neutralization resistance. In follow up work to his earlier study demonstrating robust 
protection of humanized mice against the CXCR4-tropic NL4-3 strain of HIV by vectored 
immunoprophylaxis (VIP)6, David Baltimore (California Institute of Technology) presented 
results in which humanized mice given VIP expressing b12 or VRC01 antibodies were 
challenged with a transmitted founder strain, REJO.c. In this experiment, significant 
protection against REJO.c infection was seen in mice expressing VRC01, but not b12, 
consistent with results obtained in vitro for these antibody/strain combinations. These results 
suggest that transmitted founder strains may not necessarily be more difficult to neutralize 
than non-founder strains in vivo, lending further support to translation of VIP in humans.
As most transmission of HIV occurs across mucosal surfaces, there has been substantial 
effort to model this process in macaques and more recently, humanized BLT mice12,13. In 
addition, recent macaque studies have implemented low-dose repetitive challenge to better 
simulate low-probability HIV transmission in humans14. During the session, Baltimore 
presented data utilizing a novel, modified humanized BLT mouse model incorporating 
repetitive low-dose intravaginal challenge with either the CCR5-tropic laboratory strain JR-
CSF, or the transmitted founder strain REJO.c. Using this model, he demonstrated that BLT 
mice given VIP expressing VRC01 or a more potent VRC01-like antibody (VRC07G54W) 
were highly resistant to intravaginal HIV challenge. Challenge of mice expressing VRC01 
or VRC07G54W resulted in 5/8 or 12/12 animals exhibiting undetectable viral load 
respectively, despite at least 15 exposures to virus. Interestingly, he observed limited CD4-
cell depletion in the peripheral blood, but substantial CD4-cell depletion in mucosal tissues 
of control animals analogous to observations in recently infected human patients15. Viral 
load assayed throughout the experiment by qPCR revealed that control mice were infected 
within six challenges with JR-CSF while the two mice expressing VRC01 that became 
infected did so only at very late time points, suggesting that VRC01 expression provided 
substantial protection from mucosal transmission. More strikingly, all of the mice expressing 
VRC07G54W were protected against as many as 20 consecutive weekly challenges with the 
REJO.c transmitted molecular founder strain and showed no signs of viral load by a 
commercial viral load assay sensitive to 200 copies/mL.
Challenges for Prophylactic Proteins
Multiple studies have described the potential for proteins with different antibody-based 
architectures to neutralize HIV. Among these architectures, immunoadhesins, consisting of 
the fusion of a single-chain Fv to an IgG Fc domain, have demonstrated potent activity in a 
macaque SIV-challenge model5. This architecture has the advantage of a single, compact 
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coding region that enables it to be delivered by self-complementary AAV vectors, which 
have limited carrying capacity5. However, recent studies have reported that conversion of 
full-length antibodies into immunoadhesins can negatively impact neutralization potency16. 
Phil Johnson presented results comparing an immunoadhesin form of PG9 to the native IgG 
architecture in which he found that the immunoadhesin exhibited 10 fold reduced 
neutralization potency. As a result of this, Johnson suggested that natural antibody 
architectures might be preferred for further clinical development.
The PG9 antibody recognizes a V2/V3 epitope on the HIV envelope trimer and its activity is 
highly dependent on the presence of specific glycans17. The original description of this 
family of antibodies noted that for certain viral strains, complete neutralization activity was 
not observed, regardless of antibody concentration1. This was subsequently ascribed, at least 
in part, to glycan heterogeneity of the Env spike. To determine the extent of this behavior, 
Burton presented data from experiments testing a variety of antibodies against large virus 
panels. He concluded that the behavior, which was limited, was most apparent for PG9-like 
and MPER antibodies but was relatively rare for many PGT antibodies recognizing glycans 
as well as CD4 binding site antibodies. Ultimately, the significance of viral glycan 
heterogeneity for the antibody gene transfer approach is uncertain, but it probably should be 
factored into the choice of selecting antibody combinations for prophylaxis.
Improved Antibodies
Prior to the latest patient-derived bNAbs that reinvigorated the field, soluble bi- or tetra-
valent forms of CD4 were among the most potent protein-based anti-HIV reagents. Michael 
Farzan (Harvard University) presented studies on the fusion of such a reagent with a co-
receptor mimetic peptide. HIV-1 co-receptors (CCR5 and CXCR4) share amino-terminal 
domains that include sulfotyrosines, which bind to a conserved site on gp120. The heavy-
chain CDR3 regions of several antibodies targeting the co-receptor binding site of gp120 
also include sulfotyrosines, and sulfopeptides based on these CDR3 regions can bind gp120 
and neutralize HIV-1. A fusion of one such peptide with the CD4-Ig, dubbed “eCD4-Ig”, 
was at least as potent as the current generation of anti-HIV Abs and neutralized not only all 
neutralization resistant (all Tier 2 and 3) HIV-1 strains, but also both HIV-2 and SIV 
isolates. Additionally, it significantly outperformed CD4-Ig and IgGb12 in an assay of 
antibody-dependent cell-mediated cytotoxicity (ADCC).
The dramatic breadth of eCD4-Ig presumably relates to its narrow targeting of HIV’s 
conserved receptor and co-receptor binding sites, in contrast to antibodies, which generally 
rely on contacts with less conserved regions of Env. In the context of AAV-based gene 
delivery, eCD4-Ig is small enough to be delivered by self-complementary AAV vectors. 
Macaque studies are now being undertaken to determine the utility of eCD4-Ig in 
prophylactic and therapeutic contexts.
Pamela Bjorkman (California Institute of Technology) presented studies using structure-
based design to improve the potency of CD4 binding site antibodies, as well as to overcome 
common escape mutations the virus acquires to evade these antibodies. Antibody NIH45-46, 
a more potent variant of VRC01, contains an insertion that contacts the inner domain of 
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gp120 and contributes to its greater activity compared to VRC01. Noticing that both 
NIH45-46 and VRC01 failed to fill a conserved hydrophobic pocket on gp120 that is filled 
by Phe43 of CD4, a mutant of NIH45-46 that substituted a Glycine for Tryptophan at 
position 54 was designed and found to be about 10-fold more potent than the parent 
antibody against a cross-clade panel of difficult to neutralize viruses18.
Highly potent VRC01-like antibodies, which have been isolated from at least 5 individuals, 
derive from the same germline gene, VH1-2*02. Bjorkman described key shared features of 
these antibodies, including a short CDR L3 loop and characteristic heavy chain residues 
(Trp50, Asn58, Arg71, and Trp100B). These residues are critical for initial binding of the 
VH1-2*02 germline to its HIV-1 target and explain the restricted VH gene segment usage of 
this class of antibodies19. The lack of genes with these features in laboratory animals 
suggests that attempts to test vaccines designed to induce these antibodies may need to be 
performed in mice with human antibodies genes.
Viruses resistant to VRC01-like antibodies often have mutations at sites contacted by 
characteristic residues. This observation was used to design antibody variants that could 
neutralize such viruses. One such antibody, 45–46m2, neutralizes 96% of HIV strains in a 
cross-clade panel and neutralizes a set of viral isolates resistant to all other known bNAbs20. 
A second mutant, 45–46m7, designed to thwart resistance from NIH45-46G54W, restores 
neutralization of consensus escape mutants, thus effectively targeting a common route of 
HIV escape. Bjorkman emphasized that finding a few well-chosen substitutions capable of 
dramatically improving natural bNAbs demonstrates that such antibodies are not necessarily 
optimal as isolated, raising the possibility of continued improvements using structure-based 
design methods. In addition, raising the percent of viral isolates neutralized from ~90% 
(VRC01 and related antibodies) to 96% suggests achieving nearly100% breadth may be 
possible.
Antibodies as a Treatment?
Although the meeting primarily dealt with the potential of antibody gene delivery to prevent 
HIV-1 infection, Michel Nussenzweig (The Rockefeller University) presented studies 
exploring the possibility that antibodies might also be used to treat established infections21. 
Anti-retroviral therapy has been a resounding success, but daily dosing, side effects, and 
resistance to antiretroviral drugs suggest that alternatives should be investigated.
Earlier studies demonstrated that the first generation of bNAbs (b12, 2G12, 4E10 and 2F5) 
were of limited efficacy as therapeutics in humans or in humanized mice because escape 
variants emerged within a short period of time. To examine the potential of more potent 
antibodies to function as therapeutic agents, the Nussenzweig laboratory made use of 
humanized-mice engrafted with hematopoietic stem cells and then infected with a CCR5-
tropic HIV-1YU222.
Groups of mice were treated with either a single antibody (among five different bNAbs) or 
combinations of three or five antibodies. Antibodies targeting several different epitopes 
were utilized: NIH45-46G54W, PG16, PGT128, 10-1074 (a more potent variant of PGT121), 
and 3BC176, which recognizes a conformational, but yet to be defined epitope.
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Nussenzweig reported that as in previous studies, HIV-1 escaped rapidly from treatment 
with a single antibody for all of the antibodies tested. However the viruses that escaped 
showed a limited number of genetic alterations in sites targeted directly by the antibodies. 
Moreover, combinations of five broadly neutralizing antibodies (bNAbs) were found to 
effectively control HIV-1 infection and suppress viral load to levels below detection during 
the entire therapy period of up to 60 days. In contrast to antiretroviral therapy (ART)23–25, 
the longer half-life of antibodies led to viremic control for an average of 60 days after 
cessation of therapy. Nussenzweig concluded that combinations of potent monoclonal 
antibodies can effectively control HIV-1 replication in humanized mice, and he suggested 
that they should be re-examined as a therapeutic modality in HIV-1-infected individuals.
Prospects for Human Trials
In light of the encouraging results being reported by multiple groups in animal models of 
HIV transmission, there is substantial interest in accelerating translation of these findings to 
both humans as well as animals through clinical trials (Box 1). However, this promising 
approach carries with it a number of unique challenges that must be addressed before proof 
of principle can be achieved in humans. Given the seemingly permanent nature of AAV 
transduction in animal models, there are heightened concerns surrounding the choice of 
antibody transgene for immunoprophylaxis. Several groups have reported natural poly- or 
auto-reactivity of some of the broadly neutralizing antibodies, and certain improvements in 
potency via structure-based design have resulted in enhanced auto-reactivity. Though poly-
reactivity is not an uncommon feature of natural anti-HIV antibodies26, there are concerns 
regarding off-target toxicity and effect on antibody half-life. To address these concerns, 
evaluation of antibody proteins in humans by passive transfer to confirm safety and activity 
prior to delivery by viral vectors may be warranted. Despite such testing, the possibility of 
rare adverse events may spur the development of immunoprophylaxis vectors capable of 
regulating, or eliminating antibody expression in such cases. Ultimately, adverse events may 
be minimized as a result of improvements in antibody potency, which substantially reduce 
the serum concentrations necessary to achieve sterilizing protection in animals. Potency 
improvements would have the added benefit of reducing the potential costs of VIP by 
enabling lower vector doses to be administered to patients.
Two separate Phase I trials are currently under development involving AAV for the 
expression of antibody from muscle tissues. Phil Johnson, who is leading one of these trials 
has completed discussions with the FDA to conduct a trial of AAV1 expressing PG9 
antibody from muscle in high risk, seronegative patients. Clinical grade manufacturing of 
this vector has been completed and the trial is expected to commence in the near future. 
David Baltimore, in partnership with the Vaccine Research Center at the NIH, is planning a 
separate trial of AAV8 expressing a CD4 binding site antibody from muscle in infected 
patients receiving treatment with antiretroviral drugs. During the session he revealed that 
efforts are currently underway to identify manufacturing capacity for vector production and 
to finalize the design of the trial.
In spite of the challenges, a successful demonstration of gene transfer-based 
immunoprophylaxis could alter the landscape of vaccine development and provide a new 
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pathway for tackling challenging vaccine targets like Hepatitis C, pandemic Influenza and 
Malaria. The ever-expanding universe of antibodies targeting not only infectious diseases, 
but also aberrant forms of endogenous proteins may lead to the development of entirely new 
prophylactic and therapeutic interventions that could have a major impact on protecting 
patients from disease.
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An AIDS Vaccine for Wild Chimpanzees?
Beatrice Hahn (Univ. of Pennsylvania) described the negative impact that simian 
immunodeficiency virus (SIVcpz) has on wild chimpanzee populations. Although some 
SIV strains do not cause pathology in their natural hosts, Hahn presented evidence that 
chimpanzees infected with SIVcpz have a 10 to 16 fold increased risk of death, and can 
develop pathology similar to end-stage AIDS. In wild chimpanzee populations already 
jeopardized by habitat loss and poaching, SIVcpz could pose a serious additional threat. 
Indeed, one chimpanzee community in Gombe National Park, Tanzania, where SIVcpz 
prevalence has consistently been over 40%, has suffered dramatic population decline 
over the past four decades. Accompanying the loss of wild populations, such as those in 
Gombe, will be the loss of decades of behavioral and other research performed at these 
unique sites.
HIV infection can be controlled by anti-retroviral therapy; however, treating wild 
chimpanzees with daily medication is infeasible. While there is no effective SIV vaccine, 
AAV-mediated antibody gene transfer offers a potential approach. This method might be 
practical for wild chimpanzees because a single dose of AAV administered by dart could 
potentially be sufficient to induce long-lasting antibody expression. The success of VIP 
could be monitored non-invasively, with fecal screening for secreted antibodies and by 
testing for new SIVcpz infections.
AAV-mediated gene delivery to control SIVcpz infection would require highly potent 
and broadly neutralizing anti-SIVcpz reagents. To identify such reagents, Hahn and 
colleagues utilized a panel of 11 SIVcpz infectious molecular clones (IMCs), 1 SIVgor 
IMC, and 3 HIV-1 control IMCs to test for antibody neutralization. They screened nearly 
50 monoclonal antibodies known to broadly and potently neutralize HIV-1. Generally, 
these antibodies had little neutralizing activity on the SIVcpz IMC panel. The only 
effective neutralizers were CD4 D1–D2-containing reagents, the best of which included a 
fused sulfopeptide as described in the presentation by Farzan. These reagents may be 
considered for an antibody-mediated vaccine for wild chimpanzees that could protect 
certain endangered populations from simian AIDS, and the outcome of VIP in 
chimpanzees may also inform human studies.
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Figure 1. Comparison of prophylaxis approaches
Traditional vaccines work by engaging the adaptive immune system to produce a response 
that recognizes the administered antigen. Vectored immunoprophylaxis employs a viral 
vector, such as Adeno-Associated Virus (AAV), to deliver the genes encoding for a given 
antibody into muscle cells that express the desired antibodies - and secrete them into the 
circulation – without employing the immune system. Adapted from an illustration prepared 
by La Vanguardia, Barcelona.
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